Direct-to-consumer dental startup SmileDirectClub closes down 28% on its first day of trading, after raising $1.35B in its IPO at a $9B valuation
Lauren Debter / Forbes :
Context & Ripple Effects
SmileDirectClub's public-market debut closes the arc that began with its $380M private round at a $3.2B valuation in October 2018 and continued through its IPO filing last month. The company priced at roughly triple that private mark — a $9B valuation on a $1.35B raise — and public investors immediately marked it down 28%, meaning every buyer at the offer price started underwater.
The repricing lands in a year when consumer-facing health platforms have had mixed receptions: So-Young International closed up 31% on its first day back in May, while SmileDirectClub's aligner-by-mail model — remote monitoring instead of in-office orthodontics — now faces the discipline of quarterly public reporting.
First-order effects
- SmileDirectClub banks $1.35B of new capital despite the drop, but IPO-price buyers absorb a 28% loss before the company files a single earnings report.
- Late-stage investors who entered at the $3.2B private valuation remain well ahead even after the debut slide, while the gap between the $9B offer price and the closing price resets expectations for what public buyers will pay for the model.
Second-order effects
- Adjacent dental-consumer plays such as Beam Dental — which ties insurance pricing to brushing data from its connected toothbrush — face a public-market read on whether venture-scale valuations survive contact with retail investors in consumer health.
- Competitors in remote-monitored care get a free datapoint on how heavily the market discounts growth over profitability, shaping whether they pursue early listings or stay private longer.
Third-order effects
- If the pattern holds — private rounds tripling valuations within a year of listing, then first-day markdowns — the disclosure-to-P&L gap becomes the defining test for consumer-health IPOs: public markets will demand a visible path from subscriber growth to durable economics that private backers never priced in.
- A cold reception for one direct-to-consumer health debut raises the odds the next cohort prices more conservatively or delays, shifting leverage toward later-stage investors over founders at exit.
The trend: Consumer-health startups are reaching public markets faster than their unit economics mature, making first-day trading a referendum on the gap between venture-era valuations and disclosed financials.